M-Insightlogo
  • Multiple Myeloma & MRD
    dropmenu
    What is Multiple Myeloma?
    MM is a blood cancer characterized by the clonal expansion of plasma cells in the bone marrow. Myeloma is rare, accounting for 1% of all cancers.
    dropmenu
    MM diagnosis and monitoring
    Multiple myeloma diagnosis and monitoring are based on clinical symptoms and a variety of laboratory tests. M-protein detection and quantification are integral parts of diagnosis and monitoring of MM.
    dropmenu
    What is MRD ?
    MRD stands for Minimal Residual Disease. It refers to the very small number of myeloma cells that are present in the bone marrow after treatment. These remaining cells often cannot be detected through traditional tests of treatment response. However, they have the potential to multiply and cause relapse.
  • M-inSight®
  • Resources
  • About us
    dropmenu
    Corgenix
    Contracted Services to Improve Patient Outcomes
    dropmenu
    Sebia
    The new language of life
  • Contact us
  • How to order?
    • Order M-inSight®
  • Multiple Myeloma & MRD
  • M-inSight®
  • Resources
  • About us
  • Contact us
  • How to order?
  • Order M-inSight®
  • Back
  • What is Multiple Myeloma?
  • MM diagnosis and monitoring
  • What is MRD ?
  • Back
  • Corgenix
  • Sebia

Catégorie: Publications

February 2025

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with MM – Pharmaceutics 2025
August 2023

Development of a Targeted MS Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies – J Proteome Res. 2018
June 2023

MRD Monitoring by Targeted Mass Spectrometry Allows Early Relapse Detection in MM – Blood 2022
June 2023

Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for MRD Monitoring in MM – Clin Chem. 2021
June 2023

Mass Spectrometry for Identification, Monitoring, and MRD Detection of M-Proteins – Clin Chem. 2020
June 2023

Multiple Myeloma MRD Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow – Clin Chem. 2021
June 2023

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry – Blood Cancer J. 2023
See what others can't
Order M-inSight®

Multiple Myeloma & MRD

Multiple Myeloma MRD Monitoring Diagnosis and Monitoring

M-inSight®

Discover M-inSight® Ordering information Resources Contact us
© 2025 M-inSight®
Terms of Use
Privacy policy
Privacy Practices
Claims presented in the website are supported by references on the Resources page.